Isolated Growth Hormone Deficiency (IGHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Isolated Growth Hormone Deficiency (IGHD) Market Outlook

Thelansis’s “Isolated Growth Hormone Deficiency (IGHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Isolated growth hormone deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Isolated Growth Hormone Deficiency (IGHD) Overview

Isolated Growth Hormone Deficiency (IGHD) leads to childhood growth failure due to inadequate growth hormone (GH) action. IGHD can be caused by different mutations in genes and inherited differently. Most IGHD cases are sporadic and caused by hypothalamic or pituitary insults. Symptoms of IGHD vary in type and severity among affected individuals and include anterior hypopituitarism, delayed skeletal maturation, short stature, frequent infections in type III, delayed eruption of teeth, poor growth of nails, and increased cholesterol and LDL levels in the blood. IGHD type 1 is further classified into sub-types 1a and b, with IGHD type 1a being the most severe. IGHD type 2 is inherited in an autosomal dominant pattern and is often considered the most common form of IGHD, excluding idiopathic GHD. IGHD type 3 is an X-linked recessive disorder with a highly variable phenotype. IGHD type IA is caused by GH1 gene mutations and is inherited in an autosomal recessive manner. IGHD type IB can be caused by GH1 or GHRHR gene mutations and inherited in an autosomal recessive manner. IGHD type II is caused by mutations in the GH1 gene and can be inherited in an autosomal dominant manner. IGHD type III is caused by BTK gene mutations and is inherited in an X-linked recessive pattern.

• The incidence of IGHD is estimated to be 1 per 10,000 live births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: